Biogen Q3 Beats Market, Cuts FY25 Earnings View Below Street

Biogen (BIIB) reported stronger-than-expected third-quarter results, with adjusted EPS of $4.81 and revenue of $2.54 billion, both surpassing analyst estimates. However, the biotechnology company trimmed its fiscal 2025 adjusted earnings per share forecast to $14.50-$15.00, down from $15.50-$16.00 and below Street expectations, while simultaneously raising its 2025 revenue growth outlook to flat to 1% at constant currency. This revised guidance, attributed to a stronger underlying business outlook and planned investments from Q4 business development, led to a pre-market share decline of approximately 1.3%.

Analysis

Biogen (BIIB) delivered a strong third quarter, with adjusted earnings per share of $4.81 significantly beating analyst estimates of $3.88. Total revenue grew 3% year-over-year to $2.54 billion, also surpassing the $2.34 billion forecast, driven by 67% growth in launch products across Alzheimer's, rare disease, and postpartum depression.

However, the company issued a mixed fiscal 2025 outlook, trimming adjusted EPS guidance to $14.50-$15.00 from $15.50-$16.00, falling below Street expectations of $15.76. Simultaneously, Biogen raised its 2025 revenue growth view to flat to 1% at constant currency, attributing the revised guidance to a stronger underlying business and planned Q4 business development investments.

This strategic pivot towards investment, despite a positive underlying business and improved revenue prospects, suggests a near-term impact on profitability. The market reacted negatively to the lowered earnings forecast, with Biogen shares declining approximately 1.3% in pre-market trading, reflecting investor concern over the immediate earnings outlook.

Key Decisions for Investors

• Investors should assess whether the anticipated long-term growth from Q4 business development investments justifies the near-term reduction in fiscal 2025 adjusted EPS guidance.
• Monitor the specifics of upcoming business development transactions and their potential impact on Biogen's pipeline and market positioning, as these are key to future revenue growth and profitability.
• Evaluate the sustainability of the 67% year-over-year growth in launch products, as this segment is a critical driver for the improved revenue outlook.